Individual and Family Discount Dental Plans, Affordable
Dental Care Starting at $79.95 a Year!
1-888-632-5353 
M-F 8 AM - 9 PM EST 

Find Plans in Your Area
 
ZIP code
 

Find Dentists in Your Area
 
ZIP code
 
Dentist last name
(optional)
 




you are here: DentalPlans.com > Dental Health Articles > FDA Approval > FDA Approves New Formulation of Imitrex Sumatriptan Succinate Injection

FDA Approves New Formulation of Imitrex Sumatriptan Succinate Injection
New Imitrex Injection
Updated: 2/7/2006 9:51:34 AM
 
The United States Food and Drug Administration (FDA) has approved a new formulation of Imitrex Injection that allows a convenient way for patients to take a 4mg dose using the Imitrex STATdose System(R). Imitrex Injection is indicated for the acute treatment of migraines with and without aura in adults.

As many as 28 million Americans suffer from migraine headaches. Migraines can vary from person to person and from attack to attack, therefore the treatment needs for each attack may also vary. Because relief can mean the difference between debilitating pain and the ability to resume activities of daily life, it is important for migraine sufferers to have a variety of treatment options.

Oral treatments can be effective at treating migraine pain for many patients, but for certain types of migraine attacks, an alternative delivery system, such as an injection, may be a more appropriate treatment choice. These attacks include:

-- Morning migraines -- when patients awaken with an already moderate to

severe headache

-- Approximately 48 percent of migraine attacks occur between 4 a.m.

and 9 a.m.

-- Migraines with nausea and/or vomiting

-- Approximately 92 percent of patients reported experiencing nausea

during at least one of their attacks, and approximately 68 percent

reported vomiting during at least one of their attacks

-- Rapidly escalating migraines

"The availability of Imitrex Injection provides a simple and effective treatment option for patients who experience certain types of migraines," said Robert Kaniecki, MD, director of The Headache Center at the University of Pittsburgh and assistant professor of neurology. "Migraine patients who experience nausea or vomiting with their headaches often require an injection, since oral treatments are typically not well tolerated by these patients. Additionally, injections bypass the digestive system and enter the bloodstream quickly, which is especially important for treating certain migraine attacks, such as morning and rapidly escalating migraines."

About The Imitrex STATdose System(R)

Imitrex Injection is available in the easy-to-use Imitrex STATdose System, which allows patients to conveniently administer a 4mg dose of Imitrex with just the push of a button. Previously, patients did not have a convenient way to administer doses lower than 6mg by injection.

The Imitrex STATdose System includes two small, disposable cartridges pre-filled with a single dose of Imitrex, and an easy to use autoinjector pen that allows patients to self-administer the medication about one-quarter inch under the skin. With the Imitrex STATdose System patients can treat migraines quickly and conveniently while avoiding direct contact with a needle or syringe.

According to a study published in Headache, 88 percent of patients found the Imitrex STATdose System easy to use.

"I've suffered with migraines for the last fifteen years and do not respond well to oral treatments due to the nausea I experience with each attack, so I use Imitrex Injection," said migraine patient Kimberly McGonigle. "With the Imitrex STATdose System, I can quickly and easily treat my migraines, so that I can get on with my life."

About Imitrex Injection 4mg

The efficacy of the 4mg dose of Imitrex Injection was established in three double-blind studies of adult patients with acute migraine, with or without aura. In the largest of these studies, 577 migraine patients with moderate to severe migraine pain received Imitrex Injection 4mg or placebo. This study demonstrated that 67 percent of patients received headache relief (defined as reduction in pain from moderate/severe to mild/no pain) within one hour (compared to 25 percent for placebo), and some reported relief starting in 10 minutes.

About IMITREX

Patients should not take Imitrex if they have certain types of heart disease, history of stroke or TIAs, peripheral vascular disease, Raynaud syndrome, or blood pressure that is uncontrolled. Patients with risk factors for heart disease, such as high blood pressure, high cholesterol, diabetes or are a smoker, should be evaluated by a doctor before taking Imitrex. Very rarely, certain people, even some without heart disease, have had serious heart related problems. Patients who are pregnant, nursing, or taking medications should talk to their doctor.

About GlaxoSmithKline

GlaxoSmithKline, with U.S. operations are in Philadelphia and Research Triangle Park, N.C., is one of the world's leading research-based pharmaceutical and health care companies. The company is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Source: GlaxoSmithKline

© 2006 HealthNewsDigest.com

Customer Care - 1-888-632-5353 Toll Free

  
Additional Articles
Taxotere Receives FDA Approval for the...
Advancis Pharmaceutical Receives FDA of...
FDA Approves Rituxan The First Targeted...
FDA Approves New Formulation of Imitrex...
FDA Approves New Treatment for and...
Lilly seeks FDA approval of Cymbalta...
Food labels to list allergens
Limited anti-cancer claims for products...
FDA approves combination vaccine
FDA Approves Tercicas Increlex for by...
FDA Approves Enablex for Treatment of...
Eloxatin Receives FDA Approval for the...
FDA Approves Fosrenol to Reduce Levels...
FDA Approves First Artificial Disc for...
FDA Approves Diovan valsartan to Reduce...
FDA Expands Indication for ADDERALL XR...
Sipping Soft Drinks and Other Beverages...
Schering Plough Announces FDA Approval...
FDA Approves Vesicare solifenacin for...
First Laser Gum Disease Procedure to...
FDA Approves Updated Labeling for...
FDA Approves REMICADE® for Ninth...
FDA Approves First Portable Non-Egg to...
Members of FDA Advisory Committees of...
LDR Spine™ Receives FDA 510(k) for and...
FDA Approves New Dosing Options for...
Say No To Nausea
FDA Approves Aldara
VISX CustomVue Hyperopia Procedure by...
FDA Approves Orthofix for Cervical-Stim
Shire receives US FDA approval of for...
Researchers find new target for gum ...
Toothpaste ingredients to avoid
Colorado gears up to fight tooth decay
Nebraska moves toward better dental ...
Signs that it's time to call the oral ...
Don't ignore oral health during ...
Smokers are less likely to visit the ...
Keep these dental health basics in mind...
Dentists work to teach kids about care ...

Add to Google MSN FDA Approval  Add FDA Approval To My Yahoo  Subscribe with Bloglines   Subscribe in NewsGator Online FDA Approval News Feed

The materials and articles published on DentalPlans.com are for informational purposes only. Although DentalPlans.com strives to be accurate and complete, the information is provided without liability for errors. DentalPlans.com does not warrant the accuracy or completeness of the information, text graphics, links, or other items contained on DentalPlans.com.

DentalPlans.com expressly disclaims liability for errors or omissions in these materials and DentalPlans.com makes no commitment to update the information on DentalPlans.com.

DentalPlans.com expressly disclaims all liability for the use or interpretation by others of information on DentalPlans.com. Decisions based on information contained on DentalPlans.com are the sole responsibility of the visitors, and visitors agree to hold DentalPlans.com and its Affiliates harmless against any claims for damages arising from decisions visitors make on such information.

Nothing on DentalPlans.com constitutes medical advice or other forms of advice. DentalPlans.com assumes no responsibility for material created or published by third parties linked to DentalPlans.com with or without DentalPlans.coms knowledge.

Let's Get Connected
Like Us on Facebook Follow Us on Twitter DentalPlans.com Blog, Dental Insurance Alternatives View Our YouTube Channel
Email Me Savings & Updates
Submit
Privacy Policy
The DENTALPLANS.COM website is administered by DENTALPLANS.COM, INC., a licensed Florida Discount Medical Plan Organization, 8100 S.W. 10th Street Suite #2000, Plantation, FL 33324. Plans and Programs offered by DentalPlans.com are not health insurance policies. Plans and Programs offered by DentalPlans.com provide discounts at certain health care providers for medical services. Plans and Programs offered by DentalPlans.com do not make payments directly to the providers of medical services. The Plan or Program member is obligated to pay for all health care services but will receive a discount from those health care providers who have contracted with the Plan, Program or discount plan organization.
Special promotions including but not limited to additional months free and Membership Rewards® points from American Express are not available to California residents.

© 1999-2011 DentalPlans.com, Inc. All Rights Reserved. Patents Pending. Blue Cross and Blue Shield of Florida is an Independent Licensee of the Blue Cross and Blue Shield Association.
BBB Rating A+    McAfee SECURE sites help keep you safe from identity theft, credit card fraud, spyware, spam, viruses and online scams